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Abstract	
	
Histological	 classification	 of	 brain	 tumours	 using	 the	 World	 Health	 Organization	 (WHO)	
system	 is	 the	 gold	 standard	 for	 treatment	 decision.	 Dizzying	 developments	 in	 molecular-
genetic	technology	and	research	have	rapidly	advanced	our	current	understanding	of	neuro-
oncology.	As	a	consequence,	the	WHO	has	invited	their	expert	panels	to	revise	the	current	
classification	system	of	tumours	of	the	nervous	system	and	to	introduce	for	the	first	time,	a	
molecular-genetic	approach	for	selected	tumour	entities,	thus	setting	a	new	gold	standard	in	
histopathology.	 In	May	2016,	 the	 revised	4th	 Edition	of	 the	 “blue	book”	 for	brain	 tumours	
was	released	and	will	have	a	major	impact	in	stratifying	diagnosis	and	treatment.	However,	
as	 in	 previous	 editions,	 low	 grade	 neuro-epithelial	 tumours	 presenting	 with	 a	 mixed	
neuronal	and	glial	phenotype	and	early-onset	epilepsy	as	 the	major	neurological	 symptom	
(herein	 designated	 as	 low-grade	 epilepsy-associated	 neuro-epithelial	 tumours,	 LEAT)	 have	
not	been	the	subject	of	significant	histological	or	molecular-genetic	 innovations,	which	will	
be	critically	reviewed	by	the	Neuropathology	Task	Force	of	the	International	League	against	
Epilepsy	 (ILAE).	 The	 Task	 Force	 also	 proposes	 a	 roadmap	 of	 how	 to	 develop	 a	 clinically	
meaningful	and	 integrated	clinico-pathological-genetic	classification	system	for	LEAT	 in	 the	
near	future.	
	
	
	
Introduction		
	
The	 WHO	 series	 of	 organ-specific	 tumour	 classification	 systems	 is	 the	 gold	 standard	 for	
histological	 tumour	 typing,	and	compiled	 in	 the	“blue	book	series”.	Hence,	 timely	updates	
are	 required	 for	 each	 tumour	 entity	 to	 take	 account	 of	 improved	 knowledge	 of	 the	
underlying	 pathomechanisms	 and	 best	 patient	 management	 as	 new	 targets	 for	 precision	
medicine	become	available.	In	May	2016,	the	revised	WHO	classification	of	tumours	of	the	
central	nervous	system	was	released1,	2	and	has	already	revolutionized	the	arena	of	neuro-
oncology.	 It	 is	 for	 the	 first	 time	 in	 the	 blue	 book	 series	 of	 brain	 tumours	 that	molecular-
genetic	 information	 is	required	for	an	 integrated	phenotypic-genotypic	diagnosis3,	and	this	
applies	to	diffusely	infiltrating	glial	and	embryonal	tumours.	Capacity	building	for	molecular-
genetic	analysis	 is	an	ongoing	challenge,	but	many	centres	around	 the	world	have	already	
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implemented	 this	 new	 concept.	 Increasing	 availability	 of	 immunohistochemical	 surrogates	
for	molecular	genetic	alterations4	will	also	help	in	the	practical	application	of	the	new	WHO	
classification	 system.	 It	 was	 the	 consensus	 of	 the	 WHO	 panel	 to	 acknowledge	 the	 rapid	
developments	in	neuro-oncology	since	the	breakthrough	discoveries	of	1p/19q	co-deletions	
as	 diagnostic,	 prognostic	 and	 predictive	 biomarker	 in	 oligodendrogliomas	 5-8,	 followed	 by	
discovery	 of	 MGMT	 (O6-methylguanine-DNA	 methyltransferase)	 hypermethylation	 in	
glioblastomas	 as	 a	 predictive	 biomarker	 for	 treatment	 response	 to	 temozolomide9,	10,	 and	
the	discovery	of	the	R132H	mutation	in	the	IDH1	gene	in	diffuse	gliomas	11,	12,	which	can	also	
be	detected	immunohistochemically	13,	14.The	growing	number	of	randomized	trials	for	best	
treatment	of	brain	tumours,	in	which	patients	were	stratified	by	molecular-genetic	analysis	
of	 microscopically-reviewed	 surgical	 tissue,	 were	 most	 helpful	 to	 validate	 clinically	
meaningful	patient	cohorts11,	15-18.		
	
However,	 this	 successful	 multidisciplinary	 strategy	 has	 not	 been	 developed	 nor	
systematically	 applied	 for	 LEAT,	 and	 tumour	 entities	 lacking	 ample	 evidence	 for	 distinct	
molecular-genetic	 signatures	have	 fallen	behind	 this	 rapidly	developing	process.	 The	ever-
expanding	 gulf	 between	 Virchow’s	 original	 concepts	 of	 cellular	 pathology	 (as	 a	 subjective	
diagnosis	based	on	education	and	experience)	and	the	evolving	era	of	molecular	pathology	
(as	an	objective	diagnosis	obtained	 from	 laboratory	 tests)	will	 further	divide	 the	 field	 into	
tumours	with	a	targeted	tumour	therapy	based	on	defined	molecular	alterations	and	those	
without.	The	latter	applies	in	particular	to	rare	low-grade	tumour	entities.	These	are	difficult	
to	 recruit	 prospectively	 in	 sufficiently	 large	 series	 to	 generate	meaningful	 survival	 data	 in	
reasonable	 time	 periods.	 Indeed,	 ‘neurodevelopmental	 tumours’	 with	 a	 mixed	 glial	 and	
neuronal	 phenotype,	 a	 benign	 course,	 temporal	 lobe	 localization,	 and	 seizure	 onset	 at	 a	
young	 age	 as	 a	major	 clinical	 symptom	 did	 not	meet	 current	WHO	 criteria	 for	 integrated	
histological	 and	 genetic	 classification.	 Such	 “low-grade	 epilepsy-associated	 brain	 tumours	
(LEAT)”	 cover	 a	 large	 spectrum	 of	 neuropathological	 entities	 (Table	 1),	 and	 represent	 the	
second	 largest	group	of	patients	submitted	to	epilepsy	surgery19.	The	 International	League	
against	 Epilepsy	 (ILAE)	 has	 charged	 its	 Commission	 on	 Diagnostic	 Methods	 and	
Neuropathology	 Task	 Force	 to	 address	 this	 controversial	 topic	 and	we	will	 discuss	 herein	
both,	conceptual	benefits	of	an	integrated	phenotypic-genotypic	approach	and	also	how	to	
bridge	the	current	knowledge	gap.	
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The	2016	WHO	classification	system:	what’s	new? 
	
The	2016	WHO	classification	includes	a	number	of	novel	tumour	entities,	such	as	the	diffuse	
midline	glioma,	H3K27M	mutated	(WHO	IV°)	with	predominantly	astrocytic	differentiation,	
occurring	mostly	in	children20.	The	presence	of	a	K27M	mutation	in	either	histone	H3F3A	or	
HIST1H3B/C	 is	 mandatory	 for	 the	 diagnosis	 of	 this	 tumour.	 With	 respect	 to	 epilepsy-
associated	brain	tumours,	a	gangliocytic	tumour	was	recently	reported	in	a	total	of	12	adults	
presenting	with	 temporal	 lobe	 epilepsy21,	22.	 This	 lesion	 is	 now	 included	 in	 the	WHO	 blue	
book	under	the	name	of	“multinodular	and	vacuolating	neuronal	tumour	of	the	cerebrum”.	
There	 is	 no	 grade	 assigned	 yet	 and	 it	 is	 unclear	 if	 it	 is	 neoplastic	 or	 hamartomatous.	 It	 is	
beyond	the	scope	of	this	review,	however,	to	systematically	list	all	newly	introduced	tumour	
entities.	The	most	important	innovation	in	the	new	WHO	2016	classification	is	the	panel	of	
molecular	 genetic	 tests	 added	 to	 the	neuropathologist’s	 armamentarium	 for	 studying	 and	
classifying	brain	tumours2,	and	which	has	also	helped	to	discover	clinically	meaningful	new	
entities17.	 The	 integrated	 histopathology	 report	 should	 describe,	 therefore,	 not	 only	 the	
cellular	 (microscopic)	 composition	 of	 tumour	 tissue	 but	 also	 their	 molecular	 (genetic)	
signature3.	As	a	prominent	example,	a	genetically	driven	tumour	classification	applies	for	all	
diffuse	 astrocytic	 and	 oligodendroglial	 tumours.	 The	 histological	 discrimination	 between	
astrocytomas,	oligodendrogliomas	and	mixed	oligo-astrocytomas	has	provoked	longstanding	
controversy	 in	 past	 decades	 in	 trying	 to	 decipher	 strict	 histological	 criteria	 in	 both	 low	or	
high	 grade	 subtypes	 23.	 It	 has	 been	 long	 recognized	 that	 the	 so	 called	 clear	 cell	
(“oligodendroglial”)	 component	was	 associated	with	 a	 better	 response	 to	 chemotherapy6,	
yet,	interobserver	agreement	during	histological	work-up	of	surgical	brain	tumour	specimens	
remained	poor24.	To	solve	this	ongoing	controversy,	the	WHO	now	refers	to	IDH	and	1p/19q	
as	molecular-genetic	markers	to	objectively	differentiate	the	spectrum	of	histopathologically	
diverse	 gliomas	 into	 clinically	 meaningful	 subgroups.	 Clinical	 trials	 confirmed	 that	 IDH1	
mutated	gliomas	have	a	better	prognosis	than	IDH1	wildtype25	and	that	1p/19q	co-deletions	
are	strongly	associated	with	favourable	outcome	in	patients	with	anaplastic	gliomas23,	26.	
	
The	2016	WHO	classification	system:	what’s	old?	
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Low-grade	epilepsy	associated	neuro-epithelial	tumours	remain	an	ever	challenging	issue	for	
histopathological	 classification	 throughout	 all	 editions	 of	 the	 WHO	 blue	 book,	 with	 a	
remarkable	 history	 of	 newly	 introduced	 tumour	 entities	 (Table	 2).	 These	 tumours	 consist	
mostly	 of	 neuronal	 and	 mixed	 neuronal-glial	 variants	 as	 well	 as	 supratentorial	 low-grade	
gliomas	(see	Table	1).	As	a	group,	early-onset	drug-resistant	epilepsy	(mean	of	<	15	years)	is	
often	the	patient’s	major	or	only	neurological	symptom19,	27.	Another	differentiating	feature	
from	 diffusely	 infiltrating	 gliomas	 are	 the	 tumour’s	 frequent	 localization	 in	 the	 temporal	
lobe.	 This	 group	 of	 tumours	 has	 been	 previously	 termed,	 and	 is	 nowadays	 recognized	 as	
long-term	 epilepsy-associated	 tumours	 (LEAT)28,	 with	 gangliogliomas	 (GG)	 and	
dysembryoplastic	neuroepithelial	tumours	(DNT)	as	prominent	examples.	The	term	LEAT	was	
originally	introduced	by	the	Bonn	Epilepsy	Centre	because	of	a	long	history	of	drug-resistant	
epilepsy	(>	2	years)	and	the	epilepsy	surgery	approach	(i.e.	intent	to	treat	epilepsy)	in	all	of	
their	 patients	 28.	 Meanwhile,	 the	 clinical	 definition	 for	 “epilepsy”	 and	 “drug	 resistant	
epilepsy”	has	changed	29,	30,	as	has	the	concept	of	epilepsy	surgery	as	last	treatment	resort31,	
32.	We	suggest,	therefore,	to	change	it’s	definition	to	“low-grade	epilepsy-associated	neuro-
epithelial	 tumours	 (LEAT)”.	 However,	 this	 term	 does	 not	 meet	 the	 WHO	 concept	 for	 a	
nosological	 tumour	 classification.	 The	 same	 applies	 for	 terms	 such	 as	 “Epilepsoma”	 or	
“Epileptoma”19,	33.	Compared	to	malignant	gliomas,	meningiomas	or	brain	metastases,	LEAT	
are	 rare,	 representing	 approximately	 2-5%	 of	 the	 entire	 brain	 tumour	 cohort34.	 However,	
they	are	the	second	most	common	lesion	in	patients	submitted	to	epilepsy	surgery.	The	very	
broad	 histological	 spectrum	 of	 these	 neoplasms	 is	 another	 intriguing	 observation.	 This	
relates	 to	 their	 variable	 composition	 of	 astroglia,	 oligodendroglia,	 other	 clear	 cells	 or	
neurones,	 inflammatory	cellular	 infiltrates,	calcification	or	protein	aggregation,	and	also	to	
their	variable	patterns	of	papillary,	rosetted,	or	nodular	growth	(Figure	1).	Diffuse	infiltration	
with	clusters	remote	from	the	tumour	mass	is	another	frequent	observation19,	27.	Associated	
focal	 cortical	 dysplasia	 has	 been	 reported	 in	 vastly	 different	 frequencies,	 thereby	
representing	another	complex	issue	in	need	of	clarification	19,	27.	Published	evidence	remains	
heterogeneous	 and	 controversial19,	 27,	 35,	 36,	 and	 the	 WHO	 panel	 could	 not	 develop	 or	
propose	 an	 integrated	 genotype-phenotype	 classification	 and	 grading	 system	 at	 present.	
Nevertheless,	with	recent	studies	advocating	adjuvant	chemo-radiation	therapy	 in	addition	
to	surgery	in	low-grade	gliomas16	it	is	becoming	increasingly	important	that	LEAT	are	clearly	
distinguishable	 from	 IDH1/2-wildtype	 low-grade	 gliomas	 to	 avoid	 any	 hazards	 of	 over-
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treatment37.	 Making	 the	 distinction	 is	 a	 challenge	 for	 the	 neuropathologist37.	 Improved	
imaging,	leading	to	earlier	surgery	before	recognition	as	an	“long-term	epilepsy-associated”	
tumour	rather	than	a	tumour	presenting	with	seizures,	sometimes	piece-meal	removal	and	
finally	the	large	variety	of	histological	appearances,	may	result	in	an	incorrect	diagnosis	as	a	
diffuse	low-grade	glioma.	
	
	
The	2016	WHO	classification	system:	what’s	blue?	
	
As	 histopathological	 classification	 systems	 will	 be	 continuously	 updated	 and	 revised,	 the	
WHO’s	current	 roadmap	 towards	better	understanding	of	 carcinogenesis	and	personalized	
treatment	needs	to	be	adopted	to	LEAT.	It	is	now	generally	accepted	and	also	recognized	in	
the	2016	WHO	classification,	that	LEATs	lack	IDH1	or	IDH2	mutations	as	well	as	1p/19q	co-
deletions11,	36,	38,	39.	Published	 literature	on	prevalent	molecular	alterations	 in	LEAT	point	to	
the	 RAS/RAF/MAPK	 pathway	 and	 the	 PI3K/AKT/mTOR	 pathway	 (Figure	 2).	 BRAF	 V600E	
mutations	were	most	consistently	reported	as	genetic	driver	in	gangliogliomas	(18-56%).	It’s	
variable	 detection	 also	 in	 DNT	 (0-50%)40-48	 may	 reflect,	 however,	 the	 aforementioned	
difficulties	in	separating	both	tumour	entities	at	the	microscopic	level	(see	also40,	49).	As	BRAF	
V600E	mutations	were	 observed	 also	 in	 pleomorphic	 xanthoastrocytomas	 42	 and	 pilocytic	
astrocytomas42,	 50,	 their	 presence	 cannot	 be	 regarded	 yet	 as	 specific	 for	 a	 given	 tumour	
entity.	 In	 DNT,	 tyrosine	 kinase	 activating	 FGFR1	 gene	 mutations	 prevail	 (58-82%)40,	 49,	
whereas	 MYB/MYBL1	 alterations	 were	 encountered	 in	 87%	 of	 angiocentric	 gliomas40,	
another	 LEAT	 tumour	 entity	 associated	 with	 drug-resistant	 epilepsy	 and	 early	 seizure	
onset51.	A	methylation-based	classification	from	visually	selected	tumour	regions	of	formalin	
fixed	 and	 paraffin	 embedded	 tissue	 represents	 a	 promisingnew	option40,	52-54,	 but	 has	 not	
been	 systematically	 applied	 and	 validated	 for	 the	 entire	 LEAT	 spectrum.	Use	of	mutation-
specific	 antibodies,	 i.e.	 directed	 against	 the	V600E	BRAF	mutation	 55,	may	help	 to	 further	
explore	the	extent	of	cellular	and	genetic	mosaicism	 46,	48,	56.	It	needs	to	be	shown,	however,	
if	such	features	also	contribute	to	the	epileptogenic	phenotype.	These	studies	need	a	careful	
design	based	on	a	validated	histopathological	classification	scheme.	
	
In	 order	 to	 further	 develop	 this	 field,	 the	 Task	 Force	 recommends	 a	 specific	 scenario	 and	
environment	for	randomized	controlled	trials	(RCT;	Figure	3),	which	are	largely	missing	in	the	
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field	of	LEAT.	Given	that	the	majority	of	these	tumours	are	rare	and	grow	slowly,	RCTs	will	
need	 to	 include	multiple	 centres	 to	 recruit	 sufficient	patient	numbers	within	a	 reasonable	
time	period.	An	additional	goal	should	be	to	develop	reference	pathology	centres	and	bio-
repositories	 of	 surgical	 brain	 specimens	 and	 matched	 blood	 samples	 across	 all	 different	
continents	to	allow	for	a	systematic	molecular	testing,	keeping	pace	with	new	technologies	
or	biomarkers	as	they	become	available.	Reliable	assessment	of	the	biological	behaviour	of	a	
given	LEAT	and	risk	for	malignant	progression	(reported	as	low	in	general	with	documented	
cases	 of	malignant	 progression57)	 needs	 clarification,	 as	 the	 current	WHO	 edition	 did	 not	
specify	 atypical	 LEAT	 variants	 (WHO	 II°).	 The	 tumour’s	 epileptogenic	 potential	 to	 irritate	
remote	 cortical	 areas	 or	 recruit	 remote	 cortical	 networks	 is	 another	 challenging	 issue	 in	
need	of	clarification.	Seizure	semiology	is	determined	by	a	tumour’s	 localization	within	the	
brain,	i.e.	in	the	mesial	or	lateral	temporal	lobe	 37.	However,	satellite	tumour	cell	infiltrates	
remote	from	the	mass	lesion,	as	described	in	CD34	immunoreactive	gangliogliomas	19,	35,	58,	
may	compromise	a	successful	postsurgical	outcome.	These	questions	should	be	addressed	in	
an	RCT	setting	with	 systematic	genotype-phenotype	analysis	which	also	help	 to	clarify	 the	
best	 time	 period	 for	 postsurgical	 drug	 withdrawal	 after	 complete	 tumour	 resection.	
Although	such	RCTs	do	not	aim	for	new	 interventional	 treatment	targets,	 they	will	help	to	
provide	 evidence	 for	 a	 comprehensive	 and	 clinically	 meaningful	 clinico-pathological	 and	
genetic	tumour	classification	scheme	in	the	near	future.	
	
ILAE’s	 Task	 Force	 for	Neuropathology	was	 charged	 to	 address	 this	 issue	 and	 to	 launch	 an	
interdisciplinary	agreement	study	for	tumour	grading	and	classification.	This	Task	Force	has	
recently	 been	 successful	 in	 the	 implementation	 of	 international	 consensus	 classification	
systems	 for	 Focal	 Cortical	 Dysplasia59	 and	 Hippocampal	 Sclerosis60	 in	 patients	 with	 drug-
resistant	 epilepsy,	 and	 also	 introducing	 a	 collaborative	 virtual	microscopy	 platform61.	 In	 a	
first	agreement	study	of	30	tumours	randomly	selected	from	a	multicentre	epilepsy	surgery	
series	 (German	 Neuropathology	 Reference	 Centre	 for	 Epilepsy	 Surgery	 in	 Erlangen),	
agreement	amongst	25	invited	colleagues	from	12	countries	experienced	in	epilepsy	surgery	
programmes	reached	only	40%	(unpublished	data,	R.	Coras	personal	communication).	Use	of	
immunohistochemical	 markers	 to	 more	 reliably	 differentiate	 histopathological	 epilepsy-
associated	 neuroepithelial	 tumours	 features,	 i.e.	 CD34	 and	MAP219,	58,	62,	 achieved	 slightly	
better	 agreement	 in	 the	 same	 series	 of	 tumour	 specimens	 (unpublished	 data,	 R.	 Coras	
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personal	 communication).	 The	 current	 situation	 is	 reminiscent,	 therefore,	 of	 that	 in	
oligodendrogliomas	 (as	 discussed	 above),	 and	we	 should	 follow	WHO’s	molecular-genetic	
vision	to	achieve	a	comprehensive	and	robust	classification	of	LEAT.		
	
	
Conclusion	
	
By	 establishing	 an	 integrated	 phenotype-genotype	 diagnosis,	 the	 new	 2016	 WHO	
classification	 system	has	 introduced	a	 substantial	 change	 in	our	 current	neuropathological	
work-up.	It	represents	a	paradigm	shift,	that	microscopic	inspection	alone	is	not	sufficiently	
reliable	 to	 predict	 the	 clinical	 course	 and	 treatment	 response	 in	 a	 given	 brain	 tumour.	 In	
young	 patients	 with	 epilepsy,	 a	 distinct	 subgroup	 of	 brain	 tumours	 can	 be	 encountered	
(herein	termed	‘low-grade	epilepsy-associated	neuro-epithelial	tumours’).	They	present	with	
a	 large	 and	 often	 mixed	 phenotypic	 spectrum	 and	 are	 difficult	 to	 classify	 by	 existing	
schemes.	 Also,	 published	 series	 have	 reported	 a	 variable	 representation	 of	 genetic	
alterations.	 Randomized	 clinical	 trials	 have	 not	 yet	 been	 performed	 to	 approve	 clinically	
meaningful	 tumour	 entities.	 Therefore,	 the	 revised	 WHO	 classification	 2016	 contains	 no	
histopathological	 or	 molecular-genetic	 advances	 in	 relation	 to	 this	 group	 of	 tumours.	
Adapting	WHO’s	vision	 is	mandatory	 to	establish	a	comprehensive	clinico-pathological	and	
genetic	 classification	 system	 for	 epilepsy-associated	 neuro-epithelial	 tumours	 in	 the	 near	
future.	
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Figure	1:	Is	it	all	in	one?	The	histopathological	spectrum	of	nodular	growth	in	
low-grade	epilepsy-associated	neuro-epithelial	tumours	
	
Legend	 to	 Figure	1:	 Three	examples	of	difficult-to-classify	mixed	neuronal-glial	 tumours	 in	
the	temporal	lobe,	characterized	by	areas	of	nodular	tumour	growth	(arrows	in	A,	C,	and	E).	
All	 patients	 suffered	 from	 intractable	 epilepsy	with	 seizure	 onset	 at	 young	 age.	A-B:	 This	
nodule	is	composed	of	unequivocal	clusters	of	ganglion	cells	(arrowhead	in	B),	not	otherwise	
explicable	 by	 anatomical	 location.	 C-D:	 Multinodular	 intracortical	 growth	 consisting	 of	
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oligodendroglia-like	cells	and	 floating	neurones	 (so-called	„specific	glio-neuronal	element“,	
arrowhead	in	D).	E-F:	Predominatly	astroglial	nodule	with	Rosenthal	fibres	(arrowhead	in	F)	
and	 protein	 droplets.	 All	 tumours	 showed	 other	 areas	 of	 diffuse	 cell	 infiltration,	 with	 or	
without	aberrant	CD34-immunoreactive	cell	 clusters.	Other	 tumours	of	 this	patient	 cohort	
presented	with	a	different	composition	of	same	cytological	features.	It	is	an	ever	challenging	
question	 in	 disease	 classification	 whether	 to	 lump	 these	 variants	 together	 as	 one	 tumor	
entity,	i.e.	„epileptoma“	or	specify	n+1	new	entities,	i.e.	ganglioglioma	vs.	DNT	vs.	composite	
glio-neuronal	 tumour	 ?	 Comprehensive	molecular	 analysis	 (in	 a	 RCT	 setting,	 Figure	 2)	will	
help	 to	 solve	 this	dilemma	 (see	 text	 for	 further	discussion).	Scale	bar	 in	A	=	1mm	(applies	
also	to	C,	E),	scale	bar	in	B	=	50µm	(applies	also	to	D,	F).	
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Figure	2	
	
	
Legend	to	Figure	2:	Genetic	alterations	commonly	found	in	LEAT	connect	2	major	pathways	
in	cell	metabolism,	 the	RAS/RAF/MAPK	pathway	 (green)	and	 the	PI3K/AKT/mTOR	pathway	
(blue).	 Upstream	 in	 receptor	 signalling,	 mutations	 of	 FGFR1	 have	 been	 described	 in	 DNT	
leading	 to	 activation	 of	 the	 RAS/RAF/MAPK	 pathway	 and	 the	 PI3K/AKT/mTOR	 pathway.	
BRAF	 is	 a	 component	 further	 downstream	 in	 the	 RAS/RAF/MAPK	 signalling	 cascade.	
Activation	of	this	pathway	by	the	V600E	mutation	leads	to	phosphrylation	of	MAPKs,	which	
phosphorylate	and	regulate	activities	of	partners	such	as	transcriptions	factors	(CREB,	c-fos)	
for	cell	proliferation	and	differentation.	These	functions	made	BRAF	and	MEK1/2	reasonable	
targets	for	therapeutic	approaches	(pink).	On	the	other	hand	activation	is	tightly	regulated	
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by	substrates	of	the	PI3K/AKT/mTOR	signalling	cascade.	Especially,	the	inhibiting	function	of	
the	2	major	complexes	TSC	and	mTOR	play	a	profound	role	in	the	regulation	of	autophagy,	
protein	 synthesis	 and	 cell	 survival.	 One	 of	 these	 transcription	 factors	 is	 c-myb/	 mybl1	
(purple)	 which	 is	 altered	 in	 angiocentric	 gliomas.	 All	 genetic	 alterations	 described	 are	
indicated	with	a	lightening	bolt.	
Abbreviations:	
-	AKT	(v-akt	murine	thymoma	viral	oncogene	homologs	1,	2,	3)	(alias:	PKB):	AKT1	(14q32);	
AKT2	(19q13);	AKT3	(1q44)		
-	DEPTOR	(8q24,	DEP	domain	containing	MTOR-interacting	protein)	
-	FOS	(v-fos	FBJ	murine	osteosarcoma	viral	oncogene	homolog)	and	FOS-like	antigen):	FOS	
(14q24);	FOSB	(19q13);	FOSL1	(11q13);	FOSL2	(2p23)	
-	GRB2	(17q25)	(growth	factor	receptor-bound	protein	2)		
-	INSR	(19p13)	(insulin	receptor))	
-	MAPK	(mitogen-activated	protein	kinase	):	MAPK1	(22q11)	(alias:	ERK2);	MAPK3	(16p11)	
(alias:	ERK1)	
-	MAP2K	(mitogen-activated	protein	kinase	kinase	1):	MAP2K1	(15q22)	(alias:	MAPKK1,	
MEK1);	MAP2K2	(19p13)	(alias:	MAPKK2,	MEK2)		
-	MDM2	(12q15)	(transformed	mouse	3T3	cell	double	minute	2,	p53	binding	protein)		
-	MYC	(8q24)	(v-myc	myelocytomatosis	viral	oncogene	homolog	(avian)	
-	MTOR	(1p36)	(mechanistic	target	of	rapamycin)	
-	PI3K	(phosphoinositide-3-kinase,	catalytic,	alpha,	beta,	delta,	gamma	polypeptide):	PIK3CA	
(3q26);	PIK3CB	(3q22);	PIK3CD	(1p36);	PIK3CG	(7q22)	
-	PKD1	(14q11)	(protein	kinase	D)	(alias:	PRKCM	(mu))	(Wang	et	al.,	2006)	
-	PTEN	(10q23)	(phosphatase	and	tensin	homolog	deleted	on	chromosome	ten)		
-	RAF	(v-raf	murine	sarcoma	viral	oncogene	homolog):	ARAF	(Xp11);	BRAF	(7q34);	RAF1	
(3p25)	
-	RAS	(RAS	viral	oncogene	homolog):	HRAS	(11p15)	(Harvey);	KRAS	(12p12)	(Kirsten);	NRAS	
(1p13)	(neuroblastoma)		
-	RHEB	(7q36)	(ras	homolog	enriched	in	brain)		
-	SOS1	(2p21)	(son	of	sevenless	homolog	1)	
-	STAT	(signal	transducer	and	activator	of	transcription):	STAT1	(2q32);	STAT2	(12q13);	STAT3	
(17q21);	STAT4	(2q32);	STAT5a	(17q11);	STAT5b	(17q11);	STAT6	(12q13)		
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-	TSC1	(9q34)	(tuberous	Sclerosis	1)		
-	TSC2	(16p13)	(tuberous	Sclerosis	2)	
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Figure	3	
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Legend	to	Figure	3:	A	useful	and	doable	scenario	for	systematic	investigations	of	meaningful	
clinico-pathological	LEAT	entities.	We	believe	that	the	basis	for	a	successfull	WHO	
classification	is	a	systematic	genotype-phenotype	assessment,	validated	by	randomized	and	
controlled	clinical	trials.	These	RCTs	can	be	also	used	to	clarify	the	benefit	of	early	AED	
withdrawal	after	complete	tumour	resection,	but	do	not	primarily	aim	at	novel	
interventional	treatment	options	(as	new	drug	targets	are	not	validated	yet	in	LEAT).	
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Table	1:	The	spectrum	of	epilepsy	–	associated	neuro-epithelial	tumours		
	
Entity	 Numbers	(%)	 Onset	 Duration	 Age	OP	
ANT	I°	 5	(0.4%)	 2.0	 13.0	 19.7	
GG	I°	 673	(48.7%)	 12.8	 12.7	 24.9	
GG	II°/III°	 77	(5.6%)	 14.2	 11.0	 26.9	
ISO	I°	 29	(2.1%)	 14.4	 17.7	 27.9	
DNT	I°	 256	(18.5%)	 14.7	 10.7	 25.2	
PA	I°	 81	(5.9%)	 14.8	 12.1	 25.1	
PXA	II°	 38	(2.7%)	 18.8	 12.2	 29.3	
OLIGO	II°/III°	 97	(7%)	 24.5	 12.5	 38.6	
ASTRO	II°/III°	 110	(8%)	 29.5	 6.7	 36.2	
Total	 1382	 16.5	 11.7	 27.9	
	
Legend	 to	 Table	 1:	 Summary	 of	 tumours	 collected	 in	 adults	 and	 children	 at	 the	 German	
Neuropathology	 Reference	 Center	 for	 Epilepsy	 Surgery	 in	 Erlangen.	 More	 than	 80%	 of	
tumours	present	with	seizure	onset	before	age	of	15	years	 (upper	6	 rows),	and	 localize	 in	
77%	 to	 the	 temporal	 lobe19,	 herein	 designated	 as	 low-grade	 epilepsy-associated	 neuro-
epithelial	tumours	(LEAT).	Early	seizure	onset	and	temporal	localization	separate	LEAT	from	
semi-benign	 and	 diffusely	 infiltrating	 gliomas	 also	 encountered	 in	 epilepsy	 surgery	 series	
(lower	3	rows).	Age	at	epilepsy	onset	(mean	in	years);	Epilepsy	duration	(mean	in	years);	Age	
at	operation	(mean	in	years);	ANT	–	angiocentric	glioma	WHO	I°;	GG	–	gangliogliomas	WHO	
I°	 -	 III°;	 GG	 II°	 is	 not	 specified	 by	 the	 WHO	 classification,	 but	 used	 as	 clinical	 diagnosis	
(‘analogue	WHO	II°’)	according	to	the	proposal	by	Blumcke	and	Wiestler35;	ISO	-	isomorphic	
astrocytoma	 variant	 (analogous	 to	 WHO	 I°63,	 64);	 DNT	 –	 Dysembryoplastic	 neuroepithelial	
tumour	WHO	I°;	PA	–	pilocytic	astrocytoma	WHO	I°;	PXA	–	pleomorphic	xantoastrocytoma	
WHO	 II°;	 OLIGO	 –	 oligodendroglioma	 including	 mixed	 glioma	 WHO	 II°	 and	 III°;	 ASTRO	 –	
diffuse	astrocytoma	subtypes	WHO	II°	and	III°.		
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Table	2:	Evolving	WHO	classification	of	neuronal	and	mixed	neuronal-glial	tumours	over	years	1979	–	2016	
	 1979	*65	 1993**66	 200067	 200768	 20161	
	
Gangliocytoma	
Composed	
predominantly	of	
mature	ganglion	
cells	
Grade	I	
unchanged	 Well	differentiated,	
slowly	growing	
neuroepithelial	
tumours	composed	of	
neoplastic,	mature	
ganglion	cells,	either	
alone	(GC	Grade	I),	or	
in	combination	with	
neoplastic	glial	cells	
(GG	Grade	I	or	II).	
Tumours	with	
anaplastic	glial	
component		“anaplastic	
GG”	Grade	III	or	IV	
Well	differentiated,	
slowly	growing	
neuroepithelial	
tumours	composed	of	
neoplastic,	mature	
ganglion	cells,	either	
alone	(GC	Grade	I),	or	
in	combination	with	
neoplastic	glial	cells	
(GG	Grade	I),	
observed	in	patients	
with	long-term	
epilepsy.	
Anaplastic	GG,	Grade	
III	
Criteria	for	Grade	II	
not	established.	
IDH1/2	
wildtype24,	26-28		
BRAF	V600E	
mutation	in	18-
56%25,	29-36	
	
Grade	I	
	
Anaplastic	GG,	Grade	
III	
	
Ganglioglioma	
Composed	of	
mature	ganglion	
cells	and	
neoplastic	glial	
cells	
Grades	I	or	II	
unchanged	
Anaplastic	
(malignant)	
ganglioglioma	
Gangliocytoma	or	
ganglioglioma	
with	anaplasia	
Grades	III	or	IV	
Ganglioglioma	with	
anaplasia	in	the	glial	
component	
Grade	III	
Dysplastic	
gangliocytoma	of	
cerebellum	
(Lhermitte-	
Duclos)	
Described	as	a	
dysplastic	variant	
of	Gangliocytoma	
Grade	I	
Described	separately	as	a	
tumour-like	lesion	
Grade	I	
Discussed	in	association	with	Cowden	Disease	
under	Familial	tumour	syndromes	
Not	clear	if	neoplastic	or	hamartomatous.	If	
neoplastic,	corresponds	to	Grade	I	
PTEN	(10q23)		
Grade	I	
Paraganglioma	
	 Identical	to	extra-adrenal	
paraganglioma	
orignating	in	filum	
terminale		
Grade	I	
unchanged	
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Desmoplastic	
infantile	
astrocytoma/	
ganglioglioma	
	 Mixed	neuronal-glial	
neoplasm	of	infancy	with	
desmoplasia	
Named	as	DIG		
Grade	I	
Glial	neoplasm	of	infancy	with	desmoplasia	named	as	DIA	
Glial	and	neuronal	neoplasm	of	infancy	with	desmoplasia	named	as	DIG	
Grade	I	
Dysembryoplastic	
neuroepithelial	
tumour	
	 Epilepsy-associated	
tumour	with	intracortical	
location,	multinodular	
architecture	and	
heterogeneous	cellular	
composition	
Grade	I	
Simple	form	with	
unique	glioneuronal	
element;		
Complex	form	with	glial	
nodules	in	combination	
with	glioneuronal	
element		
Reference	to	non-
specific	histological	
forms	(clinical	features	
and	imaging	need	to	be	
considered)	
Grade	I	
Simple	form	with	
unique	glioneuronal	
element;		
Complex	form	with	
glial	nodules	in	
combination	with	
glioneuronal	element		
Non-specific	
histological	form	
remains	controversial	
Grade	I	
IDH1/2	
wildtype24,	26-28		
BRAF	V600E	
mutation	in	(0-
50%)36,	39-48	
FGFR1	mutation	
in	58-82%40,	49	
Grade	I	
Central	
neurocytoma	
	 Intraventricular	tumour	
composed	of	uniform	
round	cells	with	
immunohistochemical	
(SYN)	and	ultrastructural	
features	of	neuronal	
differentiation	
Grade	I		
Intraventricular	tumour	
composed	of	uniform	
round	cells	with	
immunohistochemical	
(SYN)	and	
ultrastructural	features	
of	neuronal	
differentiation	
Reference	to	extra-
ventricular	examples	
Upgraded:	WHO	II°	
Intraventricular	tumour	composed	of	uniform	
round	cells	with	immunohistochemical	(SYN)	
and	ultrastructural	features	of	neuronal	
differentiation	
Grade	II	
Extraventricular	 	 	 	 Well-circumscribed	 IDH1/2	
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neurocytoma	 neoplasm	composed	
of	uniform	round	cells	
with	neuronal	
differentiation,	
located	in	brain	
parenchyma		
Grade	not	assigned	
wildtype69,	70	
Grade	II	
Cerebellar	
liponeurocytoma	
	 	 Rare	cerebellar	
neoplasm	of	adults	
with	advanced	
neuronal/neurocytic	
and	focal	lipomatous	
differentiation,	
previously	classified	as	
lipomatous	
medulloblastoma	
Grades	I	or	II	
Same	definition	as	in	previous	edition	,	but	
assigned	Grade	II	
	
TP53	missense	mutations	in	20%71	
Papillary	
glioneuronal	
tumour	
	 	 	 Tumour	composed	of	GFAP-positive	astrocytes	
lining	hyalinised	vascular	pseudopapillae	and	
synaptophysin-positive	interpapillary	
collections	of	sheets	of	neurocytes,	neurons	
and	“ganglioid”	cells	
SLC44A1-PRKCA	fusion72	
Grade	I	
Rosette-forming	
glioneuronal	
tumour	of	the	4th	
ventricle	
	 	 	 Neoplasms	of	fourth	ventricular	region	
composed	of	a)	uniform	neurocytes	forming	
rosettes	or	perivascular	pseudorosettes	and	b)	
component	resembling	pilocytic	astrocytoma	
	
IDH1/IDH2	wildtype73	
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FGFR1	mutations74	
No	KIAA1549-BRAF	fusion	or	BRAF	V600E	
mutations75	
	
Grade	I	
Multinodular	and	
vacuolating	
neuronal	tumour	
of	the	cerebrum	
	 	 	 	 Accepted	as	a	
pattern	of	
gangliocytoma,	
previously	
descibed	in	
patients	with	
epilepsy,	
predominately	in	
temporal	lobe21,	
22	
Grade	not	assigned	
Diffuse	
leptomeningeal	
glioneuronal	
tumour	
	 	 	 	 Predominant	and	
widespread	
leptomeningeal	
growth,	OLC	and	
neuronal	
differentiation	
Deletion	1p	in	
59%76,	77,		
IDH1/2	
wildtype76,	78	
KIAA1549-BRAF	
fusion	in	75%77	
Grade	not	assigned	
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Legend	 to	 Table	 2:	 BRAF	 =	 v-Raf	murine	 sarcoma	 viral	 oncogene	 homolog	 B,	 DIA	 =	 Desmoplastic	 infantile	 astrocytoma,	 DIG	 =	 Desmoplastic	
infantile	ganglioglioma,	GC	=	Gangliocytoma,	GG	=	ganglioglioma,	GFAP	=	glial	 fibrillary	acidic	protein,	 IDH	=	 isocitrate	dehydrogenase,	MAP2	=	
microtubule-associated	 protein	 2,	 NFP	 =	 neurofilament	 protein,	 NOS	 =	 not	 otherwise	 specified,	 NSE	 =	 neuron-specific	 enolase,	 OLC	 =	
oligodendroglial-like	cells,	PTEN	=	phosphatase	and	tensin	homolog,	SYN	=	synaptophysin,	TSC	=	tuberous	sclerosis	complex.	*	mentioned	tumours	
were	 classified	 under	 “Neuronal	 Tumours”	 along	 with	 Ganglioneuroblastoma	 and	 Neuroblastoma	 in	 the	 WHO‘s	 1979	 classification.	 **	 first	
appearence	of	the	chapter	entitled	“Neuronal	and	mixed	neuronal-glial	tumours”,	still	including	Olfactory	Neuroblastoma	and	its	variant	Olfactory	
neuroepithelioma.	
	
